Institut Municipal d'Investigacions Mèdiques-Hospital del Mar, Barcelona, Bellaterra, Spain.
J Clin Oncol. 2010 Nov 1;28(31):4687-96. doi: 10.1200/JCO.2009.25.3245. Epub 2010 Oct 4.
Earlier studies evaluating the effect on quality of life (QoL) of localized prostate cancer interventions included patients receiving adjuvant hormone therapy, which could have affected their outcomes. Our objective was to compare the QoL impact of the three most common primary treatments on patients who were not receiving adjuvant hormonal treatment.
This was a prospective study of 435 patients treated with radical prostatectomy, external-beam radiotherapy, or brachytherapy. QoL was assessed before and after treatment with the Short Form-36 and the Expanded Prostate Cancer Index Composite. Differences between groups were tested by analysis of variance. Distribution of outcome at 3 years was examined by stratifying according to baseline status. Generalized estimating equation models were constructed to assess the effect of treatment over time.
Compared with the brachytherapy group, the prostatectomy group showed greater deterioration on urinary incontinence and sexual scores but better urinary irritative-obstructive results (-18.22, -13.19, and +6.38, respectively, at 3 years; P < .001). In patients with urinary irritative-obstructive symptoms at baseline, improvement was observed in 64% of those treated with nerve-sparing radical prostatectomy. Higher bowel worsening (-2.87, P = .04) was observed in the external radiotherapy group, with 20% of patients reporting bowel symptoms.
Radical prostatectomy caused urinary incontinence and sexual dysfunction but improved pre-existing urinary irritative-obstructive symptoms. External radiotherapy and brachytherapy caused urinary irritative-obstructive adverse effects and some sexual dysfunction. External radiotherapy also caused bowel adverse effects. Relevant differences between treatment groups persisted for up to 3 years of follow-up, although the difference in sexual adverse effects between brachytherapy and prostatectomy tended to decline over long-term follow-up. These results provide valuable information for clinical decision making.
先前评估局部前列腺癌干预措施对生活质量(QoL)影响的研究纳入了接受辅助激素治疗的患者,这可能影响了他们的结果。我们的目的是比较三种最常见的主要治疗方法对未接受辅助激素治疗的患者 QoL 的影响。
这是一项对 435 例接受根治性前列腺切除术、外照射放疗或近距离放疗的患者进行的前瞻性研究。使用 SF-36 和扩展前列腺癌指数综合量表在治疗前后评估 QoL。通过方差分析检验组间差异。根据基线状态分层,检查 3 年时的结局分布。构建广义估计方程模型以评估治疗随时间的影响。
与近距离放疗组相比,前列腺切除术组在尿失禁和性功能评分方面表现出更大的恶化,但在尿刺激性/梗阻性结果方面更好(3 年时分别为-18.22、-13.19 和+6.38;P <.001)。在基线时存在尿刺激性/梗阻性症状的患者中,接受神经保留根治性前列腺切除术治疗的患者中有 64%得到改善。在外照射放疗组中观察到更高的肠道恶化(-2.87,P =.04),20%的患者报告有肠道症状。
根治性前列腺切除术导致尿失禁和性功能障碍,但改善了先前存在的尿刺激性/梗阻性症状。外照射放疗和近距离放疗导致尿刺激性/梗阻性不良事件和一些性功能障碍。外照射放疗还导致肠道不良事件。治疗组之间的相关差异在长达 3 年的随访期间持续存在,尽管近距离放疗和前列腺切除术之间的性功能不良事件差异在长期随访中趋于下降。这些结果为临床决策提供了有价值的信息。